Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.59 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.59 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.59 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.48 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402911 | 1.00 | MAP2K1 (0.59) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL4404605 | 1.00 | MAP2K1 (0.59) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL13186203 | 0.94 | MAP2K1 (0.58) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL3805316 | 0.93 | MAP2K1 (0.57) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL16716234 | 0.93 | MAP2K1 (0.57) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL4400373 | 0.93 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL486666 | 0.93 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL4399742 | 0.93 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL13063526 | 0.92 | MAP2K1 (0.60) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL13063551 | 0.92 | MAP2K1 (0.57) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150265679-A1 | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-09-24 | — | — | US | disclosed |
| EP-2411366-B1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2411366-B1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673919-B2 | Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2411366-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | Ardea Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010145197-A1 | NOVEL 6-ARYLAMINO PYRIDONE SULFONAMIDES AND 6-ARYLAMINO PYRAZINONE SULFONAMDIES AS MEK INHIBITORS | CHEMIZON (BEIJING), LTD. (CN) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010108652-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108652-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265679-A1 | METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR | NRAS, BRAF, KRAS | MAP2K1 259/4885MAP2K2 209/4885CHEK1 33/4885 |
| US-20120107307-A1 | DIHYDROPYRIDIN SULFONAMIDES AND DIHYDROPYRIDIN SULFAMIDES AS MEK INHIBITORS | BRAF, NRAS, MAP3K12 | MAP2K1 59/4885MAP2K2 52/4885CHEK1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.